Trials / Recruiting
RecruitingNCT07230405
A Phase II Study of SKB571 in Patients With Lung Cancer
A Phase II Study to Evaluate the Safety and Efficacy of SKB571 in Patients With Advanced Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (estimated)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKB571 for injection | SKB571 for injection is administered every 3 weeks(Q3W) until radiographic disease progression,intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first. |
Timeline
- Start date
- 2026-01-19
- Primary completion
- 2028-01-19
- Completion
- 2028-01-19
- First posted
- 2025-11-17
- Last updated
- 2026-02-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07230405. Inclusion in this directory is not an endorsement.